The DOI matches its Crossref record.
Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides
Open accessAbstract
Antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, repeated thromboembolic phenomena, and thrombocytopenia. The syndrome is believed to be caused by antiphospholipid beta-2-glycoprotein-I (β2GPI)-dependent Abs or anti-β2GPI Abs by themselves. Using a hexapeptide phage display library, we identified three hexapeptides that react specifically with the anti-β2GPI mAbs ILA-1, ILA-3, and H-3, which cause endothelial cell activation and induce experimental APS. To enhance the binding of the peptides to the corresponding mAbs, the peptides were lengthened to correspond with the site of the β2GPI epitope being recognized by these mAbs. As a result, the following three peptides were prepared: A, NTLKTPRVGGC, which binds to ILA-1 mAb; B, KDKATFGCHDGC, which binds to ILA-3 mAb; and C, CATLRVYKGG, which binds to H-3 mAb. Peptides A, B, and C specifically inhibit both in vitro and in vivo the biological functions of the corresponding anti-β2GPI mAbs. Exposure of endothelial cells to anti-β2GPI mAbs and their corresponding peptides led to the inhibition of endothelial cell activation, as shown by decreased expression of adhesion molecules (E-selectin, ICAM-1, VCAM-1) and monocyte adhesion.In vivo infusion of each of the anti-β2GPI mAbs into BALB/c mice, followed by administration of the corresponding specific peptides, prevented the peptide-treated mice from developing experimental APS. The use of synthetic peptides that focus on neutralization of pathogenic anti-β2GPI Abs represents a possible new therapeutic approach to APS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The microbiome in autoimmune diseases
De Luca, F., & Shoenfeld, Y. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13158 · Cited by 510
Self-citationde Laat, B., Derksen, R. H. W. M., Urbanus, R. T., & de Groot, P. G. (2005) · Blood · doi:10.1182/blood-2004-09-3387 · Cited by 378
Phage display technology: clinical applications and recent innovations
Azzazy, H. M. E., & Highsmith, W. E. (2002) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00343-0 · Cited by 351
Adhesion mechanism of human beta 2-glycoprotein I to phospholipids based on its crystal structure
Bouma, B. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5166 · Cited by 333
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Metadata
- Authors
- Blank, M., Shoenfeld, Y., Cabilly, S., Heldman, Y., Fridkin, M., & Katchalski-Katzir, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-04-27
- Volume
- 96
- Issue
- 9
- Pages
- 5164-5168
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1968519251
- Cited by
- 180
- References
- 0
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. https://app.cochat.ai/papers/10.1073/pnas.96.9.5164
- The paper
- Blank, M., Shoenfeld, Y., Cabilly, S., Heldman, Y., Fridkin, M., & Katchalski-Katzir, E. (1999). Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.96.9.5164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.